Select Medical Holdings Corporation (NYSE:SEM), announced that the company has completed its private placement of $110.0 million in aggregate principal amount of its 6.375% senior notes due 2021 (the “Additional Notes”) as additional notes under the indenture pursuant to which it previously issued $600.0 million of 6.375% senior notes due 2021. Select intends to use the net proceeds of the offering of the Additional Notes, together with cash on hand, to repurchase 10,000,000 shares of Holdings’ common stock from Welsh, Carson, Anderson & Stowe IX, L.P. and WCAS Capital Partners IV, L.P. at a price of $10.95 per share for an aggregate purchase price of $109.5 million and to pay related fees and expenses. Select Medical Holdings Corporation (NYSE:SEM) stock performance was 4.36% in last session and finished the day at $12.45. Traded volume was 1.02million shares in the last session and the average volume of the stock remained 841.92K shares. The beta of the stock remained 1.04. Select Medical Holdings Corporation (NYSE:SEM) insider ownership is 12.00%.

Corcept Therapeutics Incorporated (NASDAQ:CORT) was a big mover last session, as its shares rose over 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. Corcept Therapeutics Incorporated (NASDAQ:CORT) rose 7.13 percent to $4.36 Monday on volume of 1.20million shares. The intra-day range of the stock was $4.14 to $4.47. Corcept Therapeutics Incorporated (NASDAQ:CORT) has a market capitalization of $438.53million.

Novartis AG (ADR) (NYSE:NVS) plans to seek approval of a medicine for chronic heart failure sooner than expected, advancing its effort to build a portfolio of cardiac therapies. Novartis AG (ADR) (NYSE:NVS)’s stock on Mar 31, 2014 reported a increase of 4.20% to the closing price of $85.02. Its fifty two weeks range is $67.67 -$85.23. The total market capitalization recorded $206.27billion. The overall volume in the last trading session was 2.31million shares. In its share capital, NVS has 2.71billion outstanding shares.

Becton Dickinson & Co. (NYSE:BDX)’s stock had its “neutral” rating restated by Zacks in a report released on Wednesday, Analyst Ratings Network.com reports. They currently have a $120.00 price objective on the stock. Zacks‘s target price points to a potential upside of 4.22% from the stock’s previous close. On Monday, shares of Becton, Dickinson and Co. (NYSE:BDX) advanced 1.33% to close the day at $117.08. Company return on investment (ROI) is 11.30% and its monthly performance is recorded as 2.09%. Becton, Dickinson and Co. (NYSE:BDX) quarterly revenue growth is 6.84%.